Adaptive immunity, inflammation, and cardiovascular complications in type 1 and type 2 diabetes mellitus

Journal of Diabetes Research

Volumn 2013, Issue , 2013, Pages

  Pedicino, Daniela ^a   Liuzzo, Giovanna ^a   Trotta, Francesco ^a   Giglio, Ada Francesca ^a   Giubilato, Simona ^a   Martini, Francesca ^a   Zaccardi, Francesco ^a   Scavone, Giuseppe ^a   Previtero, Marco ^a   Massaro, Gianluca ^a   Cialdella, Pio ^a   Cardillo, Maria Teresa ^a   Pitocco, Dario ^a   Ghirlanda, Giovanni ^a   Crea, Filippo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; FEMALE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; AGED; CARDIOVASCULAR DISEASES; CELL LINE; COMPLICATION; IMMUNOLOGY; INSULIN RESISTANCE; MIDDLE AGED; PANCREAS ISLET BETA CELL; PATHOLOGY;

ADAPTIVE IMMUNITY; ADULT; AGED; CARDIOVASCULAR DISEASES; CELL LINE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS;

EID: 84878702803     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2013/184258     Document Type: Article

References (55)

1. Wild S., Roglic G., Green A., Sicree R., King H., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 27 5 1047 1053 2-s2.0-2342466734 10.2337/diacare.27.5.1047 (Pubitemid 38579764)
2. American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 2008 31 supplement 1 S55 S60
3. Haffner S. M., Lehto S., Rönnemaa T., Pyörälä K., Laakso M., Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. The New England Journal of Medicine 1998 339 4 229 234 2-s2.0-0032560807 10.1056/NEJM199807233390404 (Pubitemid 28350165)
4. Preis S. R., Hwang S. J., Coady S., Pencina M. J., D'Agostino R. B., Savage P. J., Levy D., Fox C. S., Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the framingham heart study, 1950 to 2005. Circulation 2009 119 13 1728 1735 2-s2.0-65349085059 10.1161/CIRCULATIONAHA.108.829176
5. Malmberg K., Yusuf S., Gerstein H. C., Brown J., Zhao F., Hunt D., Piegas L., Calvin J., Keltai M., Budaj A., Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000 102 9 1014 1019 2-s2.0-0034730110 (Pubitemid 30656008)
6. Donahoe S. M., Stewart G. C., McCabe C. H., Diabetes and mortality following acute coronary syndromes. The Journal of the American Medical Association 2007 298 7 765 775 (Pubitemid 47263159)
7. Meigs J. B., Hu F. B., Rifai N., Manson J. A. E., Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. The Journal of the American Medical Association 2004 291 16 1978 1986 (Pubitemid 38544279)
8. Goldberg R. B., Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. The Journal of Clinical Endocrinology & Metabolism 2009 94 9 3171 3182
9. Atkinson M. A., Eisenbarth G. S., Type 1 diabetes: new perspectives on disease pathogenesis and treatment. The Lancet 2001 358 9277 221 229 2-s2.0-0035928391 10.1016/S0140-6736(01)05415-0 (Pubitemid 32718550)
10. Kroder G., Bossenmaier B., Kellerer M., Tumor necrosis factor alpha and hyperglycemia-induced insulin resistance. The Journal of Clinical Investigation 1996 97 6 1471 1477
11. Pradhan A. D., Manson J. E., Rifai N., Buring J. E., Ridker P. M., C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Journal of the American Medical Association 2001 286 3 327 334 2-s2.0-0035908632 (Pubitemid 32656163)
12. Freeman D. J., Norrie J., Caslake M. J., Gaw A., Ford I., Lowe G. D. O., O'Reilly D. S. J., Packard C. J., Sattar N., C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002 51 5 1596 1600 2-s2.0-0036312978 (Pubitemid 34826630)
13. Esposito K., Nappo F., Marfella R., Giugliano G., Giugliano F., Ciotola M., Quagliaro L., Ceriello A., Giugliano D., Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002 106 16 2067 2072 2-s2.0-0037109184 10.1161/01.CIR.0000034509.14906.AE (Pubitemid 35192812)
14. Goldin A., Beckman J. A., Schmidt A. M., Creager M. A., Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006 114 6 597 605 2-s2.0-33746920337 10.1161/CIRCULATIONAHA.106. 621854 (Pubitemid 44199649)
15. Biasucci L. M., Liuzzo G., Della Bona R., Different apparent prognostic value of hs-CRP in type 2 diabetic and non-diabetic patients with acute coronary syndromes. Clinical Chemistry 2009 55 2 365 368
16. Kaptoge S., di Angelantonio E., Pennells L., C-reactive protein, fibrinogen, and cardiovascular disease prediction. The New England Journal of Medicine 2012 367 14 1310 1320
17. Beckman J. A., Creager M. A., Libby P., Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. Journal of the American Medical Association 2002 287 19 2570 2581 (Pubitemid 34517204)
18. Orasanu G., Plutzky J., The pathologic continuum of diabetic vascular disease. Journal of the American College of Cardiology 2009 53 5, supplement S35 S42 2-s2.0-58549094758 10.1016/j.jacc.2008.09.055
19. Swirski F. K., Nahrendorf M., Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 2013 339 6116 161 166
20. Libby P., Inflammation in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2012 32 9 2045 2051 10.1161/ATVBAHA.108.179705
21. Crea F., Liuzzo G., Pathogenesis of acute coronary syndromes. Journal of the American College of Cardiology 2013 61 1 1 11
22. Zeng C., Shi X., Zhang B., The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. Journal of Molecular Medicine 2012 90 2 175 178 10.1007/s00109-011-0816-5
23. Jagannathan-Bogdan M., McDonnell M. E., Shin H., Rehman Q., Hasturk H., Apovian C. M., Nikolajczyk B. S., Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. Journal of Immunology 2011 186 2 1162 1172 2-s2.0-79251589063 10.4049/jimmunol.1002615
24. Winer S., Chan Y., Paltser G., Normalization of obesity-associated insulin resistance through immunotherapy. Nature Medicine 2009 15 8 921 929 10.1038/nm.2001
25. Zhang H., Potter B. J., Cao J. M., Zhang C., Interferon-gamma induced adipose tissue inflammation is linked to endothelial dysfunction in type 2 diabetic mice. Basic Research in Cardiology 2011 106 6 1135 1145 10.1007/s00395-011-0212-x
26. Liuzzo G., Kopecky S. L., Frye R. L., O'Fallon W. M., Maseri A., Goronzy J. J., Weyand C. M., Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999 100 21 2135 2139 2-s2.0-0033598675
27. Liuzzo G., Goronzy J. J., Yang H., Kopecky S. L., Holmes D. R., Frye R. L., Weyand C. M., Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000 101 25 2883 2888 2-s2.0-0034720851 (Pubitemid 30415876)
28. + CD28null T Cells in patients with acute coronary syndromes. Circulation 2004 109 10 1230 1235 2-s2.0-12144287983 10.1161/01.CIR.0000118476.29352.2A (Pubitemid 38372781)
29. Nakajima T., Schulte S., Warrington K. J., Kopecky S. L., Frye R. L., Goronzy J. J., Weyand C. M., T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation 2002 105 5 570 575 2-s2.0-0037022209 10.1161/hc0502.103348 (Pubitemid 34123430)
30. Pryshchep S., Sato K., Goronzy J. J., Weyand C. M., T cell recognition and killing of vascular smooth muscle cells in acute coronary syndrome. Circulation Research 2006 98 9 1168 1176 2-s2.0-33745014193 10.1161/01.RES. 0000220649.10013.5c (Pubitemid 43948103)
31. + CD28null T lymphocytes and recurrence of acute coronary events. Journal of the American College of Cardiology 2007 50 15 1450 1458 2-s2.0-34848881869 10.1016/j.jacc.2007.06.040 (Pubitemid 47494592)
32. + CD28null T-lymphocytes in diabetic patients: exploring new pathogenetic mechanisms of increased cardiovascular risk in diabetes mellitus. European Heart Journal 2011 32 10 1214 1226 2-s2.0-79957510243 10.1093/eurheartj/ehq499
33. Feuerer M., Herrero L., Cipolletta D., Naaz A., Wong J., Nayer A., Lee J., Goldfine A. B., Benoist C., Shoelson S., Mathis D., Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nature Medicine 2009 15 8 930 939 2-s2.0-68349148211 10.1038/nm.2002
34. Eller K., Kirsch A., Wolf A. M., Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy. Diabetes 2011 60 11 2954 2962 10.2337/db11-0358
35. Wing K., Sakaguchi S., Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nature Immunology 2010 11 1 7 13 2-s2.0-74049164847 10.1038/ni.1818
36. Ferraro A., Socci C., Stabilini A., Expansion of Th17 cells and functional defects in Tregulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011 60 11 2903 2913
37. + natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunological Reviews 2006 212 1 8 27 10.1111/j.0105-2896. 2006.00427.x (Pubitemid 44116697)
38. Tang Q., Adams J. Y., Penaranda C., Melli K., Piaggio E., Sgouroudis E., Piccirillo C. A., Salomon B. L., Bluestone J. A., Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008 28 5 687 697 2-s2.0-43049174722 10.1016/j.immuni.2008.03.016
39. + regulatory T cells in the human immune system. Nature Reviews Immunology 2010 10 7 490 500 2-s2.0-77954141914 10.1038/nri2785
40. + regulatory T cells in patients with acute coronary syndromes. European Heart Journal 2006 27 21 2530 2537 2-s2.0-33750314730 10.1093/eurheartj/ehl222 (Pubitemid 44627295)
41. Ait-Oufella H., Salomon B. L., Potteaux S., Natural regulatory T cells control the development of atherosclerosis in mice. Nature Medicine 2006 12 2 178 180 10.1038/nm1343 (Pubitemid 43214743)
42. Zhang Y., Bandala-Sanchez E., Harrison L. C., Revisiting regulatory T cells in type 1 diabetes. Current Opinion in Endocrinology, Diabetes, and Obesity 2012 19 4 271 278
43. Harris M. I., Flegal K. M., Cowie C. C., Eberhardt M. S., Goldstein D. E., Little R. R., Wiedmeyer H. M., Byrd-Holt D. D., Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998 21 4 518 524 2-s2.0-0031897103 10.2337/diacare.21.4.518 (Pubitemid 28172927)
44. Pickup J. C., Mattock M. B., Activation of the innate immune system as a predictor of cardiovascular mortality in type 2 diabetes mellitus. Diabetic Medicine 2003 20 9 723 726 2-s2.0-0642274855 10.1046/j.1464-5491.2003.00990.x (Pubitemid 41701465)
45. Bending D., Zaccone P., Cooke A., Inflammation and type one diabetes. International Immunology 2012 24 6 339 346 10.1093/intimm/dxs049
46. Wegner M., Araszkiewicz A., Piorunska-Stolzmann M., Wierusz-Wysocka B., Zozulinska-Ziolkiewicz D., Association between IL-6 concentration and diabetes-related variables in DM1 patients with and without microvascular complications. Inflammation 2013 10.1007/s10753-013-9598-y
47. Cavelti-Weder C., Babians-Brunner A., Keller C., Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012 35 8 1654 1662 10.2337/dc11-2219
48. Ridker P. M., Howard C. P., Walter V., Effects of interleukin-1 β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012 126 23 2739 2748
49. Dostert C., Ludigs K., Guarda G., Innate and adaptive effects of inflammasomes on T cell responses. Current Opinion in Immunology 2013 10.1016/j.coi.2013.02.008
50. + Tregs and T helper 1 cells in acute coronary syndromes. Clinical Immunology 2007 124 1 90 97 2-s2.0-34250628384 10.1016/j.clim.2007.03.546 (Pubitemid 46936250)
51. Cheng X., Yu X., Ding Y. J., The Th17/Treg imbalance in patients with acute coronary syndrome. Clinical Immunology 2008 127 1 89 97
52. Liuzzo G., Montone R. A., Gabriele M., Identification of unique adaptive immune system signature in acute coronary syndromes. International Journal of Cardiology 2013 10.1016/j.ijcard.2013.01.009
53. Nepom G. T., Ehlers M., Mandrup-Poulsen T., Anti-cytokine therapies in T1D: concepts and strategies. Clinical Immunology 2013 10.1016/j.clim.2013.02. 003
54. Putnam A. L., Brusko T. M., Lee M. R., Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes 2009 58 3 652 662
55. Hulme M. A., Wasserfall C. H., Atkinson M. A., Brusko T. M., Central role for interleukin-2 in type 1 diabetes. Diabetes 2012 61 1 14 22